Trial Profile
A Retrospective study evaluating biomarker expression associated with poor prognosis in patients with Metastatic Renal Cell Carcinoma treated with Sorafenib or sunitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 17 Nov 2016 New trial record
- 01 Nov 2016 Results (n=111) published in the Journal of Urology.